EJMCR. 2017; 1(September 2017): 135-139

Exceptional response after metronomic chemotherapy and palliative radiotherapy in castration-resistant prostate cancer: A case report

Authors: Alessio Giuseppe Morganti, Gabriella Macchia, Rezarta Frakulli, Andrea Milanoi, Francesco Massari, Maria Ntreta, Giambattista Siepe, Alessandra Arcelli, Silvia Cammelli, Giuseppe Zanirato Rambaldi, Michelangelo Fiorentino, Francesco Deodato.

ABSTRACT

Background Castration-resistant prostate cancer (CRPC) has a dismal prognosis. Despite treatment, median survival of these patients is around 12-22 months. Case Presentation In this report, we present the case of a 71-year-old man, with CRPC and painful bone metastases treated with an association of middle-half-body radiotherapy, androgen deprivation therapy (ADT) and cyclophosphamide-based metronomic chemotherapy. Five years after palliative radiotherapy the patient is still receiving metronomic chemotherapy and ADT. He is totally asymptomatic, with undetectable PSA values and negative 18F-Choline-PET/CT. The only side-effect was the development of non-insulin-dependent diabetes. Conclusion This treatment for its tolerability and feasibility, it could be particularly useful in older patients with CRPC. Furthermore, considering the low costs, it could be an important therapeutic option for patients living in low-resourced countries.

Keywords:
Metronomic chemotherapy, radiotherapy, prostate neoplasms, CRPC, case report


View PDF
Exceptional response after metronomic chemotherapy and palliative radiotherapy in castration-resistant prostate cancer: A case report


Authors
Alessio Giuseppe Morganti
Radiotherapy Center, Departments of Experimental, Diagnostic and Specialty Medicine - DIMES Radiation Oncology Center, University of Bologna, S.Orsola-Malpighi Hospital, Bologna, Italy
PubMed articlesGoogle scholar articles

Gabriella Macchia
Radiotherapy Unit, Fondazione di Ricerca e Cura
PubMed articlesGoogle scholar articles

Rezarta Frakulli
Radiotherapy Center, Departments of Experimental, Diagnostic and Specialty Medicine - DIMES Radiation Oncology Center, University of Bologna, S.Orsola-Malpighi Hospital, Bologna, Italy
PubMed articlesGoogle scholar articles

Andrea Milanoi
Radiotherapy Center, Departments of Experimental, Diagnostic and Specialty Medicine - DIMES Radiation Oncology Center, University of Bologna, S.Orsola-Malpighi Hospital, Bologna, Italy
PubMed articlesGoogle scholar articles

Francesco Massari
Medical Oncology Unit, Azienda Ospedaliera Universitaria, Policlinico S. Orsola-Malpighi, Bologna, Italy
PubMed articlesGoogle scholar articles

Maria Ntreta
Radiotherapy Center, Departments of Experimental, Diagnostic and Specialty Medicine - DIMES Radiation Oncology Center, University of Bologna, S.Orsola-Malpighi Hospital, Bologna, Italy
PubMed articlesGoogle scholar articles

Giambattista Siepe
Radiotherapy Center, Departments of Experimental, Diagnostic and Specialty Medicine - DIMES Radiation Oncology Center, University of Bologna, S.Orsola-Malpighi Hospital, Bologna, Italy
PubMed articlesGoogle scholar articles

Alessandra Arcelli
Radiotherapy Center, Departments of Experimental, Diagnostic and Specialty Medicine - DIMES Radiation Oncology Center, University of Bologna, S.Orsola-Malpighi Hospital, Bologna, Italy
PubMed articlesGoogle scholar articles

Silvia Cammelli
Radiotherapy Center, Departments of Experimental, Diagnostic and Specialty Medicine - DIMES Radiation Oncology Center, University of Bologna, S.Orsola-Malpighi Hospital, Bologna, Italy
PubMed articlesGoogle scholar articles

Giuseppe Zanirato Rambaldi
Radiotherapy Center, Departments of Experimental, Diagnostic and Specialty Medicine - DIMES Radiation Oncology Center, University of Bologna, S.Orsola-Malpighi Hospital, Bologna, Italy
PubMed articlesGoogle scholar articles

Michelangelo Fiorentino
Pathology Unit, Addarii Institute, Azienda Ospedaliera Universitaria, Policlinico S. Orsola-Malpighi, Bologna,Italy
PubMed articlesGoogle scholar articles

Francesco Deodato
Radiotherapy Unit, Fondazione di Ricerca e Cura
PubMed articlesGoogle scholar articles


Correspondence to:
Rezarta Frakulli. Rezarta Frakulli, Radiotherapy Center, Departments of Experimental, Diagnostic and Specialty Medicine - DIMES Radiation Oncology Center, University of Bologna, S.Orsola-Malpighi Hospital, Bologna, Italy; rezarta.frakulli@gmail.com

Publication history
Received 10 Jun 2017
Revised 23 Jul 2017
Accepted 31 Jul 2017
Published in print 22 Sep 2017

How to cite this article?

Export to EndNote Export to refMan

Pubmed Style

Morganti AG, Macchia G, Frakulli R, Milanoi A, Massari F, Ntreta M, Siepe G, Arcelli A, Cammelli S, Rambaldi GZ, Fiorentino M, Deodato F. Exceptional response after metronomic chemotherapy and palliative radiotherapy in castration-resistant prostate cancer: A case report. EJMCR. 2017; 1(September 2017): 135-139. doi:10.24911/ejmcr/1/32


Web Style

Morganti AG, Macchia G, Frakulli R, Milanoi A, Massari F, Ntreta M, Siepe G, Arcelli A, Cammelli S, Rambaldi GZ, Fiorentino M, Deodato F. Exceptional response after metronomic chemotherapy and palliative radiotherapy in castration-resistant prostate cancer: A case report. http://www.ejmcr.com/?mno=268832 [Access: October 18, 2018]. doi:10.24911/ejmcr/1/32


AMA (American Medical Association) Style

Morganti AG, Macchia G, Frakulli R, Milanoi A, Massari F, Ntreta M, Siepe G, Arcelli A, Cammelli S, Rambaldi GZ, Fiorentino M, Deodato F. Exceptional response after metronomic chemotherapy and palliative radiotherapy in castration-resistant prostate cancer: A case report. EJMCR. 2017; 1(September 2017): 135-139. doi:10.24911/ejmcr/1/32


Vancouver/ICMJE Style

Morganti AG, Macchia G, Frakulli R, Milanoi A, Massari F, Ntreta M, Siepe G, Arcelli A, Cammelli S, Rambaldi GZ, Fiorentino M, Deodato F. Exceptional response after metronomic chemotherapy and palliative radiotherapy in castration-resistant prostate cancer: A case report. EJMCR. (2017), [cited October 18, 2018]; 1(September 2017): 135-139. doi:10.24911/ejmcr/1/32


Harvard Style

Morganti, A. G., Macchia, G., Frakulli, R., Milanoi, A., Massari, F., Ntreta, M., Siepe, G., Arcelli, A., Cammelli, S., Rambaldi, G. Z., Fiorentino, M. & Deodato, F. (2017) Exceptional response after metronomic chemotherapy and palliative radiotherapy in castration-resistant prostate cancer: A case report. EJMCR, 1 (September 2017), 135-139. doi:10.24911/ejmcr/1/32


Turabian Style

Morganti, Alessio Giuseppe, Gabriella Macchia, Rezarta Frakulli, Andrea Milanoi, Francesco Massari, Maria Ntreta, Giambattista Siepe, Alessandra Arcelli, Silvia Cammelli, Giuseppe Zanirato Rambaldi, Michelangelo Fiorentino, and Francesco Deodato. 2017. Exceptional response after metronomic chemotherapy and palliative radiotherapy in castration-resistant prostate cancer: A case report. European Journal of Medical Case Reports, 1 (September 2017), 135-139. doi:10.24911/ejmcr/1/32


Chicago Style

Morganti, Alessio Giuseppe, Gabriella Macchia, Rezarta Frakulli, Andrea Milanoi, Francesco Massari, Maria Ntreta, Giambattista Siepe, Alessandra Arcelli, Silvia Cammelli, Giuseppe Zanirato Rambaldi, Michelangelo Fiorentino, and Francesco Deodato. "Exceptional response after metronomic chemotherapy and palliative radiotherapy in castration-resistant prostate cancer: A case report." European Journal of Medical Case Reports 1 (2017), 135-139. doi:10.24911/ejmcr/1/32


MLA (The Modern Language Association) Style

Morganti, Alessio Giuseppe, Gabriella Macchia, Rezarta Frakulli, Andrea Milanoi, Francesco Massari, Maria Ntreta, Giambattista Siepe, Alessandra Arcelli, Silvia Cammelli, Giuseppe Zanirato Rambaldi, Michelangelo Fiorentino, and Francesco Deodato. "Exceptional response after metronomic chemotherapy and palliative radiotherapy in castration-resistant prostate cancer: A case report." European Journal of Medical Case Reports 1.September 2017 (2017), 135-139. Print. doi:10.24911/ejmcr/1/32


APA (American Psychological Association) Style

Morganti, A. G., Macchia, G., Frakulli, R., Milanoi, A., Massari, F., Ntreta, M., Siepe, G., Arcelli, A., Cammelli, S., Rambaldi, G. Z., Fiorentino, M. & Deodato, F. (2017) Exceptional response after metronomic chemotherapy and palliative radiotherapy in castration-resistant prostate cancer: A case report. European Journal of Medical Case Reports, 1 (September 2017), 135-139. doi:10.24911/ejmcr/1/32


Share this article

Click the icon of the social media platform on which you would like to share this article.

Article Statistics

Viewed: 2383
Downloaded: 273
Cited: 0

Request permissions

If you wish to reuse any part or all of this article please contact the copyright holder, contact@ejmcr.com.

Copyright © 2018 Discover Publishing Group. All Rights Reserved.